IPO Edge hosted a fireside chat from the floor of the New York Stock Exchange with senior management from Thirty Madison . The in-person interview featured President Michelle Carnahan and CFO Quan Zhang joined by IPO Edge Editor-in-Chief John Jannarone...

Healthcare Edge sister platform IPO Edge hosted a fireside chat from the floor of the New York Stock Exchange with Catherine Roggero-Lovisi, CEO of Modern Meadow. Ms. Roggero-Lovisi spoke with IPO Edge Editor-in-Chief John Jannarone about her prior role at L’Oréal S.A., the advantages of a...

By Exec Edge Editorial Staff SAB Biotherapeutics (Nasdaq: SABS) said it saw positive results from a Phase 3 clinical trial that assessed its Covid-19 drug, SAB-185, in non-hospitalized people who were at high-risk for severe outcomes. SAB-185 demonstrated benefit in...

Healthcare Edge sister platform IPO Edge hosted a fireside chat from the floor of the New York Stock Exchange with the Juliette Han, CFO and COO of Cambrian Bio. Ms. Han spoke to Editor-at-Large Jarrett Banks about her background as a neuroscientist,...

By Daniella Parra Lunaphore said it completed CHF40 million in Series D1 funding led by Ernst-Göhner Stiftung Beteiligungen (EGSB). The Swiss life sciences company said it plans to use the funding to strengthen its portfolio offering in spatial biology and support...

  By Healthcare Edge Editorial Staff Biopharma company Ocean Biomedical (Nasdaq: OCEA) began trading publicly today after merging with a SPAC called Aesther Healthcare Acquisition Corp. (Nasdaq: AEHA). Ocean Biomedical is focused on the commercialization of assets from research universities...

Plus Therapeutics, Inc. (Nasdaq: PSTV) specializes in targeted radiation treatments Rather than traditional radiation beams, Plus uses needle-sized applicators into brain fluid Focused on brain cancer which is difficult to reach through blood-brain barrier Targets 2 rare cancers: recurrent glioblastoma...

By IPO Edge Editorial Staff Biopharmaceutical company AEON Biopharma, Inc. has raised an additional $20 million in funding from existing investors to support its going-public transaction with Priveterra Acquisition Corp. (Nasdaq: PMGM). The additional capital represents nearly half of the...

By Exec Edge Editorial Staff Immunotherapy-focused SAB Biotherapeutics, Inc. (Nasdaq: SABS) announced today that the company has received an additional $8.2 million from the U.S. Department of Defense (DoD) related to the closeout of the discontinued COVID-19 prototype research and...